Average Insider

Where insiders trade, we follow

$NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Rachel L. McMinn
CEO
107
Employees
$25.20
Current Price
$309.94M
Market Cap
52W Low$15.93
Current$25.2033.4% above low, 66.6% below high
52W High$43.66

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No transactions in the last 3 months. Sign up free to see 12 months of history.

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 12, 2026
EPS
Estimated-$1.49
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Nov 9, 2026
EPS
Estimated-$1.36
Actual-$1.05
Beat
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1